Meissa Vaccines

Meissa Vaccines: Marty Moore, Founder And Chief Executive Officer

Meissa Vaccines is a  pharmaceutical start-up company focused on advancement of unmet vaccines against viruses that cause serious human diseases, such as respiratory syncytial





BioGraph 55

BioGraph 55, Inc: Paul  Tumeh, Co-founder and CEO

BioGraph 55, Inc. is a San Francisco based early-stage target discovery and drug development biotech company focused on immuno-oncology. The company leverages a proprietary and scientifically validated (through external partners) spatial-mapping technology platform called SPARTA (Spatial Processing And Regional Tissue Analysis) that collects biological information from cellular interactions in their native environment and integrates this information with genomic and transcriptomic data to identify new drug targets. The first program aims to develop an antibody therapy that i) targets refractory, “hot” solid tumors, ii) removes local immunosuppression from “hot” tumors and iii) uses a biomarker assay to identify patients likely to benefit from monotherapy.





Inflammatix: Tim Sweeney, CEO

Inflammatix is a molecular diagnostics company developing rapid tests that read the immune system to resolve major clinical and public health challenges. We are initially focused on developing tests for acute bacterial and viral infections, and sepsis based on patent-pending biomarkers exclusively licensed from Stanford University. Beyond this initial focus, our expert bioinformatics and assay development teams are poised to build a host response-based diagnostics pipeline that includes tests for tropical infections, autoimmune diseases, transplant rejection and other conditions.










InterVenn Biosciences: Widya Mulyasasmita Chief Business Officer

InterVenn is a biomarker discovery and diagnostic company, focusing on glycoproteomics. Our technology leverages mass spectrometry, AI/machine learning, as well as the biology of post-translational modification of proteins. 
Aberrant glycosylation of proteins has been implicated in key steps of disease biology, including the hallmarks of cancer as well as inflammation cascades associated with autoimmunity and aging. Unlike DNA and RNA, glycans are structurally complex and their synthesis is not template-based. Hence, glycoproteins have been analytically and computationally challenging to study at scale. We have built a platform that overcomes these challenges while turning years of computational burden into minutes.
Our database consists of over 1,000 site-specific glycoforms of proteins circulating in the blood, to our knowledge the largest glycoproteomic database existing today. Of note, we measure >100 glycoforms of immunoglobulin isotypes, which are well known in the literature to affect various immune signaling pathways underlying many disease processes.   
Our first product is an ovarian cancer diagnostic blood test, and we have a pipeline of pilot data demonstrating diagnostic, prognostic, disease phenotyping, and pharmacodynamic biomarkers in other indications, including other cancers, immunology, fibrosis, and aging.   









StoneStable Inc. Ken Stedman, CSO and Founder

StoneStable Inc. is a Portland, Oregon based start-up that is developing vaccine stabilization technologies.  We reversibly coat vaccines in silica both to preserve the vaccine and to serve as an adjuvant. Previous research has shown silica-mediated stabilization of Vaccinia and bacteriophages with no loss of immunogenicity and minimal loss of activity. Current research foci are Yellow Fever Vaccine, other Flaviviruses, and Live Attenuated Influenza Vaccines.   StoneStable has an exclusive license to a family of internationally issued patents from Portland State University and Providence Cancer Center on silica-treated viruses.  





Avalia Immunotherapies 

Avalia is a preclinical stage biotech company developing vaccines and immunotherapies for the prevention and treatment of infectious disease and cancer. Their lead program is targeting a cure for the >250 million sufferers of chronic hepatitis B. There is currently no cure available and 25% of patients progress to complicated liver disease, which results in 1 million annual deaths worldwide. Avalia’s immunotherapy activates our immune system’s first responders, natural killer T (NKT) cells, which have the ability to generate a powerful response in the liver, the site of hepatitis infection. They are in addition developing a pipeline of candidates for malaria, influenza and oncology.








SapVax, LLC is dedicated to the development and commercialization of a pipeline of powerful, self-adjuvanting peptide-based cancer vaccines. Our proprietary platform consists of highly specific and effective, novel TLR2 agonist adjuvants covalently conjugated to virtually any synthetic long peptide antigen. Our lead vaccine, SVX-ESO, targets the well-characterized tumor antigen, NY-ESO-1, and is in late stage preclinical development for ovarian cancer. Our second lead program is in discovery stage for the development of a personalized neoantigen cancer vaccine.




Agany, Inc.

Angany is a privately-owned, pre-clinical pharmaceutical company whose goal is to bring a new generation of allergy products to the market. Angany uses a unique cGMP recombinant technology to produce pure individual allergens for in vivo diagnostic and complementary allergen biosynthetic nanoparticles for curative therapy. Angany’s allergen bioparticles are self-adjuvanted and have unique immunomodulatory characteristics that make them the first true therapeutic vaccine candidate of the allergy industry. These should represent a disruptive answer to the shortcomings of current allergenic extracts. Angany believes its nanoparticle platform will also find direct applications in cancer immunotherapy. Angany was first established in France in 2010 and later acquired by a Canadian entity. It currently has activities both in Val de Reuil (France) and Québec City (Canada). 





Vaccines are the most cost-effective form of medicine ever developed. Yet, we chronically under invest in this most valuable form of medicine. To bridge this gap Verndari is integrating proprietary sutransformational technologies combining cutting edge vaccine design with cutting edge vaccine delivery. With the addition of adjuvant, this enables us to offer the complete package of vaccine antigen + adjuvant + delivery. Verndari is focused on influenza vaccine modernization. On September 19, 2019 President Trump announced a national initiative to modernize influenza vaccines. Verndari’s approach aligns very well with the Executive Order’s objectives and specifics.  





VaxNewMo is an early stage biotechnological company developing next-generation conjugate vaccines against existing and emerging bacterial threats using our proprietary bioconjugation technology. Our platform technology supports the production of polysaccharide-protein conjugates in a simple, one-step enzymatic reaction all within the periplasm of glycoengineered strains of E. coli. Currently, VaxNewMo is developing bioconjugate vaccines for Streptococcus pneumoniae (Pneumococcus), Klebsiella pneumoniae, and Group B Streptococcus.




NTx is a Santa-Fe based R&D, bioinformatics and biomanufacturing startup company that develops and advances a unique platform for research scale to mid-scale, host-independant biological manufacturing.
The NTx platform enables high-throughput screening for and fast prototyping of novel biological materials with defined qualities. NTx expands its research and development to allow real-time metabolic profiling of bacteria, fungi, and plants to discover, characterize and produce chemical entities (NCEs) and biosimilars with increased reproducibility at a reduced footprint and accelerated time effort. The goal is to provide materials for a diverse product development and drug leads for clinical development and drug leads for clinical development, which counter infectious diseases and other health conditions that present a challenge to public health.

Contact us

To sponsor or exhibit contact:
Oliver Breed
+44 (0)207 092 1156

To speak:
Lauren Sheppard
+44 (0)207 092 1211